CBI 3rd Annual Summit on Biosimilars

Panelist on First Follow-On Biologic Exclusivity; Moderator of Panel on How Different Lengths of Exclusivity Would Affect Innovation (March 10-11, 2009).

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.